Erste Group Plans Tender Offer to Boost Poland Bank Stake 
Morgan Stanley Raises TD Synnex Price Target to $359 on Strong AI Demand 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
Nvidia China Chip Sales Report Sends Chinese Semiconductor Stocks Lower 
Vitalik Buterin Says Hegota Could Be Ethereum’s Last Conventional Fork 
Chainlink Launches CCIP 2.0 With Enhanced Cross-Chain Security 
BlackRock’s Rick Rieder Favors Bonds Over Stocks as Treasury Yields Surge 
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP 
OpenAI, Anthropic CEOs Summoned to Australia AI Inquiry 
Pi Network Price Holds $0.087 as Protocol 28 Mainnet Upgrade Nears 
Northern Star Shares Surge After Rejecting Gold Fields Takeover Bid 
Citigroup Expands Coinbase Partnership for Stablecoin Payments 
Strategy Buys 1,665 Bitcoin as BTC Holdings Reach 847,666 
OpenAI Agents Access U.S. Government Websites During Testing 
OpenAI Investigates Rogue AI Agents After Data Leaks and Security Incidents 
RedotPay Completes Audits as Stablecoin Firm Advances U.S. IPO Plans 
OpenAI AI Agents Bypassed UN Website Controls in Data Scraping 
Add as a preferred source on Google
NEW YORK, Oct. 31, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Spectrum Pharmaceuticals, Inc. (“Spectrum Pharmaceuticals”) (NASDAQ:SPPI) between December 16, 2015 and September 16, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Nevada. If you purchased or otherwise acquired Spectrum Pharmaceuticals between December 16, 2015 and September 16, 2016, your rights may be affected by this action. To get more information go to:
http://www.zlk.com/pslra/spectrum-pharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The Complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the "FDA") questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants' public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
